Financials data is unavailable for this security.
Inc stmt in GBPIncome statement in GBP
Year on year
GlaxoSmithKline PLC grew net income 205.59% from 2.76bn to 8.42bn primarily through revenue growth (23.01bn to 23.92bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 3.99% growth in revenues contributed enough to still see net income improve.
|Net profit margin||0.31%|
|Return on assets||0.14%|
|Return on equity||0.84%|
|Return on investment||0.22%|
Cash flow in GBP
GlaxoSmithKline PLC increased its cash reserves by 36.20%, or 1.46bn. Cash Flow from Investing totalled 6.04bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 2.57bn in cash from operations while cash used for financing totalled 7.10bn.
|Cash flow per share||0.3755|
|Price/Cash flow per share||43.97|
|Book value per share||0.1178|
|Tangible book value per share||-4.82|
Balance sheet in GBP
|Total debt/total equity||34.12|
|Total debt/total capital||0.8225|
Growth rates in GBP
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 204.15%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is the highest in its industry.
|Div yield(5 year avg)||0.05%|
|Div growth rate (5 year)||4.24%|
|Payout ratio (TTM)||15,635.48%|
|EPS growth(5 years)||40.15|
|EPS (TTM) vs |
TTM 1 year ago